

PINNACLE Registry®

Practice-Level Executive Summary Report

PINNACLE Registry® Metrics

0003, Test Practice_NextGen

2016Q1

[Rolling: 1st April 2015 to 31st March 2016]

Generated on 5/11/2016 11:37:35 AM

American College of Cardiology Foundation
National Cardiovascular Data Registry®

800-257-4737

ncdr.com/pinnacle

ncdr@acc.org

©2014, American College of Cardiology Foundation


PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-100 Blood Pressure Control

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who have a blood pressure $< 140/90$ mm Hg, OR who have a blood pressure $\geq 140/90$ mm Hg and were prescribed ≥ 2 antihypertensive medications during the most recent office visit (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	84.43 (347/411)	84.28 (1023040/1213901)
2015Q3	76.5 (306/400)	84.09 (1015791/1208017)
2015Q4	88.35 (364/412)	83.58 (1024281/1225445)
2016Q1	89.56 (343/383)	84.29 (886641/1051871)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-100-1 Blood Pressure Control: BPs measured under 140/90


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who have a blood pressure $< 140/90$ mm Hg (*required subtotal*)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	59.12 (243/411)	67.26 (816580/1213987)
2015Q3	51.25 (205/400)	67.44 (814692/1208112)
2015Q4	64.81 (267/412)	66.71 (817616/1225543)
2016Q1	65.27 (250/383)	66.48 (699328/1051954)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-100-2 Blood Pressure Control: 2 or more anti-hypertensive medications

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who were prescribed ≥ 2 antihypertensive medications during the most recent office visit (*required subtotal*)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	25.3 (104/411)	17.06 (207036/1213901)
2015Q3	25.25 (101/400)	16.68 (201478/1208017)
2015Q4	23.54 (97/412)	16.88 (206916/1225445)
2016Q1	24.28 (93/383)	17.83 (187563/1051871)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-101 Lipid Control

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who have an LDL cholesterol result < 100 mg/dL, OR who have an LDL cholesterol result ≥ 100 mg/dL and have a documented plan of care to achieve LDL cholesterol < 100 mg/dL, including, at a minimum, the prescription of a statin (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	69.59 (286/411)	51.89 (629612/1213322)
2015Q3	68.5 (274/400)	51.88 (626474/1207429)
2015Q4	70.39 (290/412)	52.25 (639969/1224814)
2016Q1	70.5 (270/383)	53.64 (563916/1051382)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-101-1 Lipid Control: LDL less than 100 mg/dL

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who have an LDL cholesterol result <100 mg/dL (*required subtotal*)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	52.55 (216/411)	43.62 (529493/1213987)
2015Q3	54.75 (219/400)	43.59 (526622/1208112)
2015Q4	54.61 (225/412)	43.88 (537716/1225543)
2016Q1	54.05 (207/383)	44.78 (471080/1051954)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-101-2 Lipid Control: Statin prescribed or continued

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who have an LDL cholesterol result >100 mg/dL and have a documented plan of care to achieve LDL cholesterol <100 mg/dL, including, at a minimum, the prescription of a statin (*required subtotal*)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	19.95 (82/411)	10.09 (122438/1213322)
2015Q3	13.75 (55/400)	10.22 (123438/1207429)
2015Q4	17.23 (71/412)	10.35 (126757/1224814)
2016Q1	20.37 (78/383)	10.91 (114675/1051382)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-33 Complete Lipid Profile

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease who received at least one lipid profile (ALL four numerical component values documented) within a 12-month period (date required) *ACC/AHA/PCPI (retired)*


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	37.71 (155/411)	27.39 (332558/1213987)
2015Q3	9.75 (39/400)	26.76 (323293/1208112)
2015Q4	33.5 (138/412)	26.76 (327895/1225543)
2016Q1	38.64 (148/383)	27.03 (284395/1051954)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-36 Statin Therapy

Percentage of aged ≥ 18 years with a diagnosis of coronary artery disease with a prescription of a statin (*test metric*)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	67.4 (277/411)	71.21 (863603/1212717)
2015Q3	66.75 (267/400)	71.21 (859410/1206806)
2015Q4	66.02 (272/412)	71.06 (869871/1224163)
2016Q1	64.75 (248/383)	72.42 (761038/1050868)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-102 Symptom and Activity Assessment


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period for whom there are documented results of an evaluation of level of activity AND an evaluation of presence or absence of angina symptoms (includes assessment of angina equivalents) in the medical record (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	93.43 (384/411)	43.95 (533591/1213987)
2015Q3	94 (376/400)	43.51 (525656/1208112)
2015Q4	94.42 (389/412)	44.19 (541549/1225543)
2016Q1	96.34 (369/383)	48.25 (507562/1051954)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-103 Symptom Management


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period and with results of an evaluation of level of activity, AND with an evaluation of presence or absence of anginal symptoms, with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of angina symptoms, OR evaluation of level of activity and symptoms includes report of anginal symptoms, and a plan of care is documented to achieve control of anginal symptoms) (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	100 (373/373)	87.51 (294912/337001)
2015Q3	100 (361/361)	88.69 (297031/334922)
2015Q4	100 (376/376)	90.66 (312929/345161)
2016Q1	100 (357/357)	91.72 (281000/306356)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-103-1 Symptom Management: No Anginal Symptoms


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period and with results of an evaluation of level of activity, AND with an evaluation of level of activity and symptoms includes no report of angina symptoms (*required subtotal*)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	99.73 (372/373)	81.44 (274466/337001)
2015Q3	99.72 (360/361)	82.99 (277936/334922)
2015Q4	99.73 (375/376)	85.65 (295618/345161)
2016Q1	99.72 (356/357)	86.9 (266214/306356)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-103-2 Symptom Management: Plan of Care for Anginal Symptom Control

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period and evaluation of level of activity and symptoms includes report of anginal symptoms, AND a plan of care is documented to achieve control of anginal symptoms (≥ 2 anti-anginal medications prescribed OR Referral for consideration for coronary revascularization OR referral for additional evaluation or treatment of anginal symptoms) *(required subtotal)*


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	0.27 (1/373)	8.29 (27954/337001)
2015Q3	0.28 (1/361)	7.6 (25458/334922)
2015Q4	0.27 (1/376)	6.9 (23806/345161)
2016Q1	0.28 (1/357)	6.97 (21360/306356)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-104 Tobacco Cessation and Intervention


Percentage of patients aged >=18 years with a diagnosis of coronary artery disease seen within a 12-month period who were screened for tobacco use AND received tobacco-cessation counseling if identified as tobacco users
 (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	89.05 (366/411)	90.15 (1094380/1213990)
2015Q3	90.75 (363/400)	90.39 (1092066/1208128)
2015Q4	90.78 (374/412)	90.83 (1113135/1225579)
2016Q1	91.91 (352/383)	91.28 (960312/1051995)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-105 Antiplatelet Therapy

Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who were prescribed aspirin or clopidogrel (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	59.75 (239/400)	76.27 (886835/1162728)
2015Q3	59.43 (230/387)	75.91 (878373/1157087)
2015Q4	60.45 (240/397)	75.53 (886487/1173614)
2016Q1	55.8 (207/371)	76.49 (771166/1008231)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-106 Beta Blocker Therapy: Prior MI or LVSD


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who also have prior myocardial infarction or a current or prior LVEF $< 40\%$ who were prescribed beta-blocker therapy (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	36.84 (7/19)	74.84 (192426/257114)
2015Q3	45 (9/20)	74.67 (189179/253339)
2015Q4	42.86 (9/21)	74.52 (191248/256655)
2016Q1	38.89 (7/18)	75.28 (166972/221794)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-107 ACE Inhibitor or ARB Therapy: Diabetes or LVSD


Percentage of patients aged ≥ 18 years with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes or a current or prior LVEF $< 40\%$ and who were prescribed ACE-inhibitor or ARB therapy (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	72.62 (122/168)	67.6 (266350/393999)
2015Q3	69.38 (111/160)	67.42 (263573/390969)
2015Q4	64.64 (117/181)	67.35 (267091/396596)
2016Q1	54.43 (86/158)	68.32 (232404/340171)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-108 Cardiac Rehabilitation Patient Referral from an Outpatient Setting

Percentage of patients evaluated in an outpatient setting who within the previous 12 months have experienced an acute myocardial infarction, coronary artery bypass graft surgery, PCI, cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina and have not already participated in an early outpatient CR or secondary prevention program for the qualifying event/diagnosis and are referred to such a program (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	0 (0/53)	10.87 (19244/176979)
2015Q3	0 (0/18)	11.57 (20315/175579)
2015Q4	0 (0/140)	11.58 (21429/185054)
2016Q1	0 (0/153)	10.29 (17272/167834)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-120 Blood Pressure Control

Percentage of patients aged ≥ 18 years with a diagnosis of hypertension seen within a 12-month period who have a blood pressure $< 140/90$ mm Hg, OR who have a blood pressure $\geq 140/90$ mm Hg and were prescribed ≥ 2 antihypertensive medications during the most recent office visit (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	84.18 (298/354)	80.9 (1625188/2008851)
2015Q3	77.71 (272/350)	80.27 (1621678/2020191)
2015Q4	87.53 (323/369)	79.41 (1636551/2060914)
2016Q1	90.29 (307/340)	79.72 (1427424/1790533)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-120-1 Blood Pressure Control: BPs measured under 140/90


Percentage of patients aged ≥ 18 years with a diagnosis of hypertension seen within a 12-month period who have a blood pressure $< 140/90$ mm Hg (*required subtotal*)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	59.04 (209/354)	62.69 (1259603/2009359)
2015Q3	51.71 (181/350)	62.55 (1263860/2020689)
2015Q4	63.96 (236/369)	61.63 (1270502/2061411)
2016Q1	65.29 (222/340)	61.35 (1098753/1791037)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-120-2 Blood Pressure Control: 2 or more anti-hypertensive medications

Percentage of patients aged ≥ 18 years with a diagnosis of hypertension seen within a 12-month period who were prescribed ≥ 2 antihypertensive medications during the most recent office visit (*required subtotal*)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	25.14 (89/354)	18.24 (366496/2008851)
2015Q3	26 (91/350)	17.74 (358434/2020191)
2015Q4	23.58 (87/369)	17.78 (366483/2060914)
2016Q1	25 (85/340)	18.38 (329070/1790533)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-140 LVEF Assessment


Percentage of patients aged ≥ 18 years with a diagnosis of heart failure for whom the quantitative or qualitative results of a recent or prior (any time in the past) left ventricular ejection fraction assessment is documented within a 12-month period (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	100 (42/42)	74.02 (391651/529147)
2015Q3	97.78 (44/45)	73.59 (388348/527734)
2015Q4	100 (44/44)	73.5 (396464/539419)
2016Q1	100 (41/41)	72.66 (326215/448948)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-141 Symptom and Activity Assessment

Percentage of patient visits for those patients aged ≥ 18 years with a diagnosis of heart failure with quantitative results of an evaluation of both current level of activity and clinical symptoms documented (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	73.17 (60/82)	52.02 (697720/1341207)
2015Q3	68.57 (72/105)	51.82 (694581/1340437)
2015Q4	60.19 (65/108)	52.22 (709564/1358745)
2016Q1	60.42 (58/96)	52.89 (586872/1109560)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-142 Symptom Management

Percentage of patient visits for those patients aged ≥ 18 years with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND clinical symptoms documented in which patient symptoms have improved or remained consistent with treatment goals since last assessment OR patient symptoms have demonstrated clinically important deterioration since last assessment with a documented plan of care (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)



Quarter	Practice Average	National Average
2015Q2	0 (0/0)	94.94 (289471/304888)
2015Q3	0 (0/0)	95.2 (312034/327773)
2015Q4	0 (0/0)	95.06 (331410/348638)
2016Q1	0 (0/0)	94.13 (239994/254970)

Location Performance(2016Q1)

No Data Available

Provider Performance(2016Q1)


No Data Available

PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-142-1 Symptom Management: Symptoms improved

Percentage of patient visits for those patients aged ≥ 18 years with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND clinical symptoms documented in which patient symptoms have improved or remained consistent with treatment goals since last assessment (*required subtotal*)

[View Measure Scorecard](#)



Quarter	Practice Average	National Average
2015Q2	0 (0/0)	94.93 (289438/304888)
2015Q3	0 (0/0)	95.19 (311994/327773)
2015Q4	0 (0/0)	95.05 (331376/348638)
2016Q1	0 (0/0)	94.12 (239984/254970)

Location Performance(2016Q1)

No Data Available

Provider Performance(2016Q1)


No Data Available

PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-142-2 Symptom Management: Plan of care for symptoms

Percentage of patient visits for those patients aged ≥ 18 years with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND patient symptoms have demonstrated clinically important deterioration since last assessment with a documented plan of care (*required subtotal*)

[View Measure Scorecard](#)



Quarter	Practice Average	National Average
2015Q2	0 (0/0)	0.01 (33/304888)
2015Q3	0 (0/0)	0.01 (40/327773)
2015Q4	0 (0/0)	0.01 (34/348638)
2016Q1	0 (0/0)	0 (10/254970)

Location Performance(2016Q1)

No Data Available

Provider Performance(2016Q1)

No Data Available


PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-143 Patient Self-Care Education

Percentage of patients aged >=18 years with a diagnosis of heart failure who were provided with self-care education on >=3 elements of education during >=1 visit within a 12-month period (ACC/AHA/AMA-PCPI test measure)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	2.38 (1/42)	54.45 (288110/529147)
2015Q3	2.22 (1/45)	54.45 (287362/527734)
2015Q4	2.27 (1/44)	54.66 (294872/539419)
2016Q1	2.44 (1/41)	53.52 (240262/448948)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-144 Beta Blocker Therapy: LVSD


Percentage of patients aged ≥ 18 years with a diagnosis of heart failure seen within a 12-month period with a current or prior LVEF of $< 40\%$ who were prescribed beta-blocker therapy with bisoprolol, carvedilol, or sustained-release metoprolol succinate (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	33.33 (3/9)	75.09 (69429/92455)
2015Q3	50 (4/8)	75.15 (68668/91369)
2015Q4	50 (5/10)	75.23 (69630/92558)
2016Q1	50 (5/10)	76.12 (60066/78908)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-145 ACE Inhibitor or ARB Therapy: Diabetes or LVSD


Percentage of patients aged ≥ 18 years with a diagnosis of heart failure with a current or prior LVEF of $< 40\%$ who were prescribed ACE inhibitor or ARB therapy either within a 12-month period when seen in the outpatient setting or at hospital discharge (ACC/AHA/AMA-PCPI)

[View Measure Scorecard](#)




Quarter	Practice Average	National Average
2015Q2	75 (6/8)	71.98 (65808/91429)
2015Q3	87.5 (7/8)	71.88 (64980/90406)
2015Q4	70 (7/10)	71.88 (65895/91671)
2016Q1	60 (6/10)	72.84 (57035/78301)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-146 Counseling about ICD Implementation for LVSD

Percentage of patients aged ≥ 18 years with a diagnosis of HF with current LVEF $\leq 35\%$ despite ACE inhibitor/ARB and beta-blocker therapy for at least 3 months who were counseled about ICD implantation as a treatment option for the prophylaxis of sudden death (ACC/AHA/AMA-PCPI test measure)

[View Measure Scorecard](#)

Practice Performance



Quarter	Practice Average	National Average
2015Q2	0 (0/0)	3.13 (272/8702)
2015Q3	0 (0/0)	4.11 (432/10512)
2015Q4	0 (0/0)	4.6 (560/12176)
2016Q1	0 (0/0)	5.76 (634/11013)

Location Performance(2016Q1)

No Data Available

Provider Performance(2016Q1)

No Data Available


PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-160 Assessment of Thromboembolic Risk Factors (CHADS2)

Percentage of patients aged ≥ 18 years with nonvalvular AF or atrial flutter in whom assessment of thromboembolic risk factors using the CHADS2 risk criteria has been documented (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	4.76 (2/42)	27.09 (170664/630057)
2015Q3	7.69 (3/39)	27.23 (171567/630085)
2015Q4	19.05 (8/42)	28.01 (179425/640661)
2016Q1	11.36 (5/44)	27.41 (151902/554111)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-161 Chronic Anticoagulation Therapy

Percentage of patients aged ≥ 18 years with nonvalvular AF or atrial flutter at high risk for thromboembolism, according to CHADS2 risk stratification, who were prescribed of warfarin or another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism (ACC/AHA/AMA-PCPI)


[View Measure Scorecard](#)

Practice Performance




Quarter	Practice Average	National Average
2015Q2	48.28 (14/29)	63.26 (251077/396913)
2015Q3	55.56 (15/27)	63.54 (251502/395798)
2015Q4	59.26 (16/27)	63.75 (256762/402734)
2016Q1	55.17 (16/29)	64.74 (227594/351532)

Location Performance(2016Q1)



Provider Performance(2016Q1)




PINNACLE Registry®
Practice-Level Executive Summary Report
Test Practice 0003_NextGen
2016Q1

PINN-14 Advance Care Plan


Percentage of patients aged >=65 years who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan (NCQA)

[View Measure Scorecard](#)



Quarter	Practice Average	National Average
2015Q2	94.42 (254/269)	33.1 (570511/1723619)
2015Q3	97.67 (252/258)	35.37 (606221/1713748)
2015Q4	98.8 (247/250)	39.47 (709808/1798375)
2016Q1	96.22 (229/238)	44.57 (672584/1509177)

Location Performance(2016Q1)



Provider Performance(2016Q1)

